- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01250236
Effect of Brimonidine on Corneal Thickness
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out
- whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
- whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Baden-Wuerttemberg
-
Breisach, Baden-Wuerttemberg, Germany, 79206
- Recruiting
- Augenarztpraxis
-
Contact:
- Matthias Grueb, Priv. Doz. Dr.
- Phone Number: 004976677766
- Email: matthias.grueb@web.de
-
Principal Investigator:
- Matthias Grueb, Priv. Doz. Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study
Exclusion Criteria:
- any serious medical or neurologic conditions and/or regular use of local or systemic medications
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
verum
brimonidine 0.1% eye drops twice daily
|
brimonidine 0.1% eye drops twice daily
|
placebo
sodium hyaluronate 1.8mg/ml eye drops twice daily
|
sodium hyaluronate 1.8mg/ml eye drops twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
corneal thickness
Time Frame: 5 days
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
intraocular pressure
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Matthias Grueb, Priv. Doz. Dr., Augenarztpraxis Breisach
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Grueb Klin CT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impact of Brimonidine on the Cornea
-
University of California, San FranciscoFood and Drug Administration (FDA)RecruitingThe Impact of Excipients on Drug AbsorptionUnited States
-
RWTH Aachen UniversityUnknownThe Impact of Oxytocin on Social CognitionGermany
-
ChromoLogic, LLCUniversity of California, Los AngelesCompletedThe Impact of Whole Body Irradiation on Ocular FlareUnited States
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompletedThe Impact of Adipose Tissue Quality on Fat Graft RetentionAustria
-
Filip Krag KnopUniversity of CopenhagenCompletedTo Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 SecretionDenmark
-
Ain Shams UniversityUnknownTo Evaluate the Impact of the Vaginal Ph and Acidification of Vaginal Misoprostol on Its Efficacy in Facilitating Induction of Mid-trimester Abortion.United States
-
Ospedale Regionale Bellinzona e ValliCompletedImpact of Anesthetic Choice on Costs
-
University of PennsylvaniaMerakey Behavioral HealthCompletedImpact of Feedback on Symptoms and Trust/Respect on OutcomesUnited States
-
University of OklahomaRecruitingImpact of Supervision on Endoscopy Simulation CurriculumUnited States
-
Agency for Healthcare Research and Quality (AHRQ)CompletedImpact of Electronic Prescribing on Medication SafetyUnited States
Clinical Trials on brimonidine 0.1%
-
Galderma R&DCompletedErythematous RosaceaUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
Walter Reed Army Medical CenterUnknownOcular Hypertension | GlaucomaUnited States
-
University Hospital of PatrasCompletedOcular Hypertension | Posterior Capsule OpacificationGreece
-
AllerganCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
AllerganCompletedRetinitis PigmentosaFrance, United States, Germany, Portugal
-
AllerganCompletedMacular DegenerationKorea, Republic of, Australia, Portugal, Germany, United States, Philippines, Italy
-
AllerganCompletedRhegmatogenous Macula-off Retinal DetachmentUnited Kingdom, Korea, Republic of, Israel, India, United States, Philippines
-
AllerganCompletedVitrectomyUnited States, Czech Republic
-
AllerganCompletedGlaucoma, Open-AngleIsrael, United States